TRexBio Closes $116.7M IPO to Advance Tissue-Targeted Autoimmune Therapies

SOUTH SAN FRANCISCO, CA – October 13, 2026 – The intersection of cutting-edge immunology and public market mechanics was on full display today as TRex Bio, Inc. officially closed its initial public offering, raising approximately $116.7 million in gross proceeds. Trading on the Nasdaq Global Select Market under the ticker symbol TRXB, the clinical-stage biotechnology company issued 8,333,334 shares priced at $14.00 each. The offering, managed by a heavyweight banking syndicate led by J.P. Morgan, Evercore ISI, Cantor, and Stifel, with Wedbush PacGrow acting as a book-running manager, marks a critical milestone for a company attempting to rewrite the rules of autoimmune disease treatment.

For leaders navigating the next industrial revolution in healthcare, this listing is more than just a capital raise; it is a vital indicator of investor appetite for highly targeted, platform-driven drug discovery. The South San Francisco-based firm is pioneering the use of tissue regulatory T cell (Treg) biology. Rather than relying on traditional systemic immunosuppressants that blunt the body's entire defense mechanism, the company aims to restore localized immune balance and promote tissue repair—a paradigm shift that has clearly captured the attention of both Wall Street and major pharmaceutical partners.

Decoding the Deep Biology Platform

The core engine driving this public debut is the company's proprietary Deep Biology Platform. This system decodes Treg functionality directly within human tissue, mapping the precise drivers of immune dysregulation. By understanding how these regulatory cells behave in their natural, localized environment, researchers can uncover novel therapeutic targets that inform a highly specific drug discovery process.

A significant portion of the newly acquired capital is already earmarked for clinical advancement. The firm estimates net proceeds of approximately $103.5 million—a figure that could climb to roughly $119.8 million if underwriters fully exercise their 30-day option to purchase an additional 1,250,000 shares. Of this war chest, approximately $90 million is specifically allocated to fund Phase 2 trials for the lead wholly-owned candidate, TRB-061.

TRB-061 is an investigational tumor necrosis factor receptor 2 (TNFR2) agonist. Its mechanism of action is designed to selectively expand and activate Tregs within inflamed tissues. The candidate is currently navigating a Phase 1a/b clinical trial, with the 1b portion evaluating efficacy and safety in patients suffering from moderate-to-severe atopic dermatitis. The fresh capital will propel this program through to topline data readouts and support expansion into Phase 2 trials for both atopic dermatitis and alopecia areata. Topline data from the current Phase 1b portion is anticipated by mid-2027, providing a near-term catalyst for public market investors.

Strategic Partnerships and Calculated Risks

While internal pipeline development is crucial, the company’s strategic architecture heavily features collaborations with industry titans. Eli Lilly and Johnson & Johnson have both recognized the potential of tissue Treg biology, actively partnering with the newly public biotech.

Eli Lilly’s involvement is particularly deeply entrenched. Prior to the IPO, the pharmaceutical giant was the largest equity holder, controlling approximately 23.9% of the company. Lilly is currently advancing TRB-051, a candidate originating from the Treg platform, into a Phase 2a lupus trial. This collaboration has already yielded a $15 million milestone payment in 2024, with the potential for up to $577.5 million in additional downstream milestones. Furthermore, Lilly signaled strong continued support by indicating an interest in purchasing up to $12 million worth of shares in this offering, ensuring their post-offering stake remains significant while not exceeding 19.9%.

However, the path to commercializing novel biology is rarely without friction. SEC filings associated with the offering disclosed adverse findings from recent animal studies involving TRB-061. Specifically, one monkey was found dead in a non-GLP study, and another required early euthanasia during an ongoing GLP study. The root causes of these events are currently under active investigation. One industry observer noted that while such setbacks are not uncommon in preclinical toxicology assessments, the public market's reaction to the upcoming clinical data will heavily depend on the management's ability to isolate and contextualize these animal study findings.

A Barometer for the Late-2026 Biotech Market

The mechanics of this public listing offer a fascinating window into the broader health of the biotechnology sector in the fourth quarter of 2026. The industry is currently experiencing what some analysts have dubbed a "biotech spring." Following a period of sluggish activity, U.S. biopharma IPOs have generated nearly $8 billion this year—a six-fold increase compared to the same period in 2025.

Yet, this is a discerning market. Investors are showing a distinct preference for companies armed with human clinical data and late-stage programs. The fact that the shares priced at $14.00—the low end of the initial proposed range of $14.00 to $16.00—suggests that while institutional demand was sufficient to successfully close the deal, buyers remained price-sensitive. At the final IPO price, the enterprise commands a post-money market capitalization of approximately $384 million, based on roughly 27.45 million fully diluted shares outstanding.

This pricing dynamic places the firm in an interesting cohort. It debuted simultaneously with other notable biotech listings, including Retension Pharmaceuticals and City Therapeutics, highlighting a crowded but active window for life sciences capital formation. The successful execution of the deal, even at the lower boundary of the range, indicates a functional public market willing to fund compelling, clinical-stage science.

The Institutional Appetite for Immunology

Beyond the lead asset, the management team plans to deploy approximately $10 million of the IPO proceeds to initiate and complete a Phase 1 trial for a second wholly-owned candidate, TRB-071. This asset targets CD30 to augment tissue Tregs and block inflammatory signaling, with genetic studies strongly supporting its potential application in inflammatory bowel disease. The trial, targeting healthy volunteers, is slated to begin in the first half of 2027, subject to regulatory clearance.

The executive team steering this expansive pipeline brings significant operational pedigree. CEO M. Johnston Erwin Jr. spent 36 years at Eli Lilly, notably leading Lilly New Ventures, the drugmaker's internal venture capital arm. This deep experience in both corporate strategy and venture financing is reflected in the robust syndicate of pre-IPO backers the company assembled. The cap table features prominent names including SV Health Investors, Pfizer Ventures, Johnson & Johnson Innovation, Janus Henderson Investors, Alexandria Venture Investments, Delos Capital, and Polaris Partners.

Insider participation in the IPO further underscores confidence in the platform's trajectory. Entities affiliated with SV Life Sciences purchased significant blocks of shares at the offering price, reinforcing the commitment of early backers as operations transition to the public stage. With the combined resources from this offering and its pre-existing capital—which stood at $90.9 million in cash and marketable securities as of June 30, 2026—financial modeling projects a runway extending into the second half of 2029. This extended operational horizon provides the critical time needed to generate definitive clinical data and potentially validate a new frontier in the treatment of autoimmune and inflammatory diseases.